Max Neeman International

Max Neeman International specializes in providing comprehensive clinical research services and solutions to the pharmaceutical and biotech industries, enhancing the efficiency and effectiveness of drug development processes. Founded in 2001 in New Delhi, India, Max Neeman International focuses on clinical research services. In May 2015, the company was acquired by JSS Medical Research Inc for INR 95. 89 million, which marked a significant pivot in its business strategy.

The firm has successfully completed one notable deal, with its most recent funding round occurring on January 27, 2015. The founder's history and previous ventures are not documented. Max Neeman International offers an array of clinical research services tailored to meet the needs of pharmaceutical and biotechnology companies. Its services encompass clinical trial management, regulatory affairs, and data management, all designed to support clients in navigating the complexities of drug development.

The firm operates with a focus on delivering high-quality research outcomes, ensuring compliance with global regulatory standards, and facilitating efficient project execution. In the most recent year reported, 2014, Max Neeman International generated revenue of INR 3,653,300. Max Neeman International's future growth strategy includes leveraging the recent acquisition by JSS Medical Research Inc to enhance its service offerings and expand into new geographic markets. The funding from the acquisition is aimed at developing new clinical research products and services that are expected to be launched in the upcoming years.

Specific target markets for expansion have not been detailed, but the focus will be on increasing the company's footprint in both domestic and international arenas.